radotinib   Click here for help

GtoPdb Ligand ID: 7814

Synonyms: IY-5511 | IY5511 | IY5511HCl | KB-146009 | Supect®
Approved drug
radotinib is an approved drug (South Korea (2012))
Compound class: Synthetic organic
Comment: This drug is approved only in South Korea, for the treatment of chronic myeloid leukemia (CML), where its trade name is Supect.
It is Example 5 in patent US7501424 [1]. The marketed formulation contains the hydrochloride salt..
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: radotinib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 109.99
Molecular weight 530.18
XLogP 3.77
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2nccnc2)C)cc(c1)C(F)(F)F
Isomeric SMILES Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2nccnc2)C)cc(c1)C(F)(F)F
InChI InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
No information available.
Summary of Clinical Use Click here for help
A Phase 2I clinical trial (NCT01511289) is currently recruiting participants (Nov 2014). This study will assess the efficacy of radotinib vs. imatinib in newly diagnosed philadelphia chromosome +ve chronic myeloid leukemia patients. Phase 2 trial results are reported in [2].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Radotinib's molecular mechanism of action involves inhibition of the tyrosine kinase Bcr-ABL1 fusion [3] and of platelet-derived growth factor receptor (PDGFR) activity.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01511289 Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Phase 3 Interventional Il-Yang Pharm. Co., Ltd.